ダカルバジン

5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide

HCID 2942

基本情報

CAS
4342-03-4
標準SMILES
CN(C)N=Nc1nc[nH]c1C(N)=O
InChIKey
FDKXTQMXEQVLRF-UHFFFAOYSA-N
分子式
C6H10N6O
平均分子量
182.18 g/mol
単同位体質量
182.09160896

概要

Dacarbazine can cause cancer according to an independent committee of scientific and health experts. It can cause developmental toxicity according to state or federal government labeling requirements.

名称と識別子

優先名称
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
IUPAC
4-(dimethylaminodiazenyl)-1H-imidazole-5-carboxamide
現地名
ダカルバジン
英語名
Dacarbazine
分子式
C6H10N6O
分子量
182.18

名称と別名

(E)-5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide750512-03-95- (3,3-Dimethyl-1-triazenyl) imidazole-4-carboxamide(E)-DacarbazineDtic-Dome (TN)DTIESMR000857131Dacarbazinum [INN-Latin]Dacarbazino [INN-Spanish]C6H10N6ODimethyltriaTox21_201010
名称をさらに表示
ダカルバジンデチセン1-(4-カルバモイル-1H-イミダゾール-5-イル)-3,3-ジメチルトリアゼン5-(3,3-ジメチル-1-トリアゼニル)-1H-イミダゾール-4-カルボアミド5-(3,3-ジメチル-1-トリアゼノ)-1H-イミダゾール-4-カルボアミド5-(3,3-ジメチルトリアゼノ)イミダゾール-4-カルボキシアミドダカルバジン (JAN)ダカルバシン5-(3,3-ジメチルトリアザ-1-エン-1-イル)-1H-イミダゾール-4-カルボキサミドDTICdtic-domedeticeneWR139007dtic-aomeNSC-45388WR 139007WR-139007nci-c04717
Dacarbazine RSDacarbazine CRSMFCD000571675-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; DTIC; DIC; NSC-45388;Prestwick_904Spectrum_000884Prestwick0_000574Prestwick1_000574

データベース識別子

CAS
4342-03-4
PubChem CID
2942
DTXSID
DTXSID0020369
ChEMBL
CHEMBL1574179
ChEBI
CHEBI:4305

物性

構造計算による物性

XLogP
-0.6
極性表面積
99.7 Ų
水素結合供与体数
2
水素結合受容体数
5
回転可能結合数
3
重原子数
13

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics

LogP · 2 件

-1.6

-0.24

Solubility1.36e+00 g/L
Melting Point205 °C
Physical DescriptionSolid
Collision Cross Section142.75 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
199 · 199-205°C
沸点
315.57 °C · 315.57°C (rough estimate)
比重(密度)
1.3206 · 1.3206 (rough estimate)
屈折率
1.75 · 1.7500 (estimate)
貯蔵温度
2 · 2-8°C
溶解性
水または無水エタノールに溶けにくく、塩化メチレンにほとんど溶けない。

化学的性質

化学的特性Dacarbazine is a white to ivory-colored crystalline solid.

安全と法規制

安全データ

wgk
3
rtecs
NI3950000
hs_code
29349990
risk_code
45-46-20/21/22-36/37/38
消防法
危-5-II
hazard_code
T,Xi,Xn

化学と産業

薬理情報

Metabolism/MetabolitesDacarbazine has known human metabolites that include MTIC.
Cellular LocationsCytoplasm
応用分野 · 5 件

用途アルキル化剤です。代謝で生 じたジアゾメタンを介したアルキル化作用に より DNA の障害を引き起こします。

用途がん研究用試薬。

説明Dacarbazine is nevertheless considered the first representative of the series of triazene derivatives. It has been shown that it is an alkylating agent, and thus this drug inhibits RNA and protein synthesis to a greater degree than DNA. Dacarbazine is used intravenously for Hodgkin’s disease, soft-tissue sarcoma, and metastatic melanoma. A synonym of this drug is diticene.

使用Dacarbazine is used as an antineoplastic for treatment of malignant melanoma and sarcomas.

一般的な説明Dacarbazine is available in 100- and 200-mg vials for IVadministration in the treatment of Hodgkin’s disease, malignantmelanoma, carcinoid cancer, neuroblastoma, andsoft tissue sarcoma. Resistance to dacarbazine has been primarilyattributed to enhanced activity of AGAT. The volumeof distribution exceeds the amount of water in thebody suggesting the compound distributes into body tissuespossibly the liver. The agent is not highly protein bound(20%) and is metabolized in the liver by CYP to give MTICand 4-amino-5-imidazole-carboxamide (AIC).Thedemethylation reaction is mediated by isozymes CYP1A1/2and CYP2E1. Elimination occurs via the urine with 40% to50% occurring as unchanged drug. Dose-limiting myelosuppressionpresents as both leucopenia and thrombocytopenia.Other adverse effects include nausea, vomiting,flulike symptoms, photosensitivity, and pain at the injectionsite.

サプライヤー100 社

国药集团化学试剂有限公司86-21-63210123 · [email protected]
北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
合肥翰刚医药科技有限公司+8618062405514 · [email protected]
補足説明 · 1 件

定義ChEBI: A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs or the treatment of Hodgkin's disease and soft-tissue sarcoma.

関連反応

0 件

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…